If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-22. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Ab–Ah === John Jacob Abel (1857–1938). American biochemist and pharmacologist. He founded and chaired the first department of pharmacology in the United States at the University of Michigan. Robert Abeles (1926–2000). American biological chemist at Brandeis University. Member Natl. Acad. Sci. USA. John Abelson (b. 1938). American biologist at Caltech, with expertise in biophysics, biochemistry, and genetics, and known for work on RNA splicing. Sir Edward Abraham CBE, FRS (1913–1999). English biochemist at the University of Oxford involved in the development of penicillin and cephalosporin Gary Ackers (1939–2011). American Professor of Biochemistry and Molecular Biophysics at Washington University in St. Louis, who worked on thermodynamic linkage analysis of biological macromolecules. Gilbert Smithson Adair FRS (1896–1979). British protein chemist at the University of Cambridge, the first to identify cooperative binding, in the context of oxygen binding to haemoglobin. Julius Adler (1930–2024). American Professor of Biochemistry and Genetics at the University of Wisconsin–Madison, known for work on chemotaxis. David Agard (20th–21st century). American Professor of Biochemistry and Biophysics at UC San Francisco, whose research is focussed on understanding the basic principles of macromolecular structure and function. Member Natl. Acad. Sci. USA. Natalie Ahn (PhD 1985).
The light-nanosecond is defined as exactly 29.9792458 cm. It was popularized in information technology as a unit of distance by Grace Hopper as the distance which a photon could travel in one billionth of a second (roughly 30 cm or one foot): "The speed of light is one foot per nanosecond."
Research on PFOA has demonstrated ubiquity, animal-based toxicity, and some associations with human health parameters and potential health effects. Additionally, advances in analytical chemistry in recent years have allowed the routine detection of low- and sub-parts per billion levels of PFOA in a variety of substances. In 2013, Gore-Tex eliminated the use of PFOAs in the manufacture of its weatherproof functional fabrics. Major companies producing PFOA signed with the Global PFOA Stewardship Program with the goal of elimination of PFOA by 2015. Since then it has been eliminated from the production of non-stick materials used in cookware. GenX has been introduced as a replacement for PFOA, but in a 2015 study which tested the effects on rats, GenX caused many of the same health problems as PFOA, but required much higher concentrations. This is because GenX (C3) is a short chain alternative to PFOA. GenX also has a significantly shorter half-life than PFOA so it is not as bio-persistent as PFOA or other long chain perfluorinated chemicals.
Sources: en.wikipedia.org
=== ISCEA Expansion into Latin America === In 2006 Seguro Popular, a governmental health-care institution created in 2002; issued an RFID technology mandate to authenticate and improve drug safety within its supply chain. ISCEA served as RFID technical advisor to the Mexican government providing guidance on best practices to implement RFID technology in Seguro Popular's Supply Chain Model, and also providing with RFID Supply Chain Manager (RFIDSCM) certification to Mexican Pharma Manufacturers and Distributors looking to comply with the mandate. Seguro Popular was later replaced by Insabi during the administration of President Andrés Manuel López Obrador, but ISCEA's presence has been expanding in Mexico and other Latin American countries ever since. ISCEA has been active in the region through partnerships with Universities and Associations, delivering awards, participating in supply chain events and contributing with articles to supply chain media in Mexico,
=== Wet media milling (nanocrystal technology) === In wet media milling, the drug substance is suspended in an aqueous solution containing a stabilizing surfactant or polymer and circulated through a chamber filled with small (typically 0.2–0.5 mm) ceramic, glass, or polymer-coated beads. Bead-on-bead and bead-on-particle impacts progressively reduce the drug particle size to the 100–400 nm range, while the stabilizer adsorbs onto newly created surfaces and prevents agglomeration. The technology, commercialized as NanoCrystal by Elan Drug Technologies (later Alkermes), underpins several U.S. Food and Drug Administration–approved products, including sirolimus (Rapamune oral tablet, approved 2000), aprepitant (Emend, 2003), fenofibrate (Tricor 145 mg, 2004; Triglide, 2005), and megestrol acetate (Megace ES, 2005).
=== Atomic number === In chemistry, the number of protons in the nucleus of an atom is known as the atomic number, which determines the chemical element to which the atom belongs. For example, the atomic number of chlorine is 17; this means that each chlorine atom has 17 protons and that all atoms with 17 protons are chlorine atoms. The chemical properties of each atom are determined by the number of (negatively charged) electrons, which for neutral atoms is equal to the number of (positive) protons so that the total charge is zero. For example, a neutral chlorine atom has 17 protons and 17 electrons, whereas a Cl− anion has 17 protons and 18 electrons for a total charge of −1 e. All atoms of a given element are not necessarily identical, however. The number of neutrons may vary to form different isotopes, and energy levels may differ, resulting in different nuclear isomers. For example, there are two stable isotopes of chlorine: 3517Cl with 35 − 17 = 18 neutrons and 3717Cl with 37 − 17 = 20 neutrons.
==== Aquaporin ==== The currently known aquaporins cluster loosely together as do the known glycerol facilitators. MIP family proteins are believed to form aqueous pores that selectively allow passive transport of their solute(s) across the membrane with minimal apparent recognition. Aquaporins selectively transport glycerol as well as water while glycerol facilitators selectively transport glycerol but not water. Some aquaporins can transport NH3 and CO2. Glycerol facilitators function as solute nonspecific channels, and may transport glycerol, dihydroxyacetone, propanediol, urea and other small neutral molecules in physiologically important processes. Some members of the family, including the yeast Fps1 protein (TC# 1.A.8.5.1) and tobacco NtTIPa (TC# 1.A.8.10.2) may transport both water and small solutes.
Sources: en.wikipedia.org
Parathyroid hormone is metabolised in the liver and to a lesser extent in the kidney. It is not excreted from the body in its intact form. Circulating carboxy-terminal fragments are filtered by the kidney, but are subsequently broken down into even smaller fragments during tubular reuptake. No studies have so far been performed in patients with severe hepatic impairment. The pharmacokinetics of parathyroid hormone in patients with severe chronic kidney disease (creatinine clearance of less than 30 ml/min) has not been investigated either.
==== Appointment and political stance ==== Thatcher was impressed by Heseltine's campaigning and love of headlines during the May 1979 election, in contrast to most of the Shadow Cabinet. After the Conservatives had won, and mindful of her earlier promise that he need not take on the Environment job in government, she offered him the Energy Department (an important job following the 1979 energy crisis caused by the Iranian Revolution). He preferred to be Secretary of State for the Environment after all, entering the Cabinet for the first time. During the macroeconomic disputes of the early 1980s, Heseltine was sometimes associated with the Cabinet "wets" (Peter Walker, Jim Prior, Ian Gilmour, Lord Carrington and Norman St John Stevas) but was not seen as one of them, nor was he invited to their private meetings. Both Nigel Lawson and Cecil Parkinson agreed in their memoirs (1992) that he accepted in principle the need to control public expenditure. He opposed the abolition of exchange controls in 1979 and opposed Geoffrey Howe's tight budget in 1981, suggesting a public sector pay freeze instead. Heseltine favoured privatisation of state owned industries, a novel idea in 1979 as the Conservatives were initially only proposing to denationalise the industries nationalised by Labour in the 1970s. Despite his initial reluctance to take on the job, Heseltine later described it as "four of the happiest years of my life". He passed the Wildlife and Countryside Act 1981, a conservation measure.
== Factors affecting ligation == In the laboratory, factors that affect an enzyme-mediated chemical reaction would naturally affect a ligation reaction, these include the concentration of enzyme and the reactants, the temperature of reaction and the length of time of incubation. Ligation is complicated by the fact that the reaction can involve both inter- and intra-molecular reactions, but the desired ligation products in many ligation reactions (e.g. ligating a DNA fragment into a vector) needed first to be inter-molecular, i.e. between two different DNA molecules, followed by an intra-molecular reaction to seal and circularize the molecule. For efficient ligation, an additional annealing step is also necessary. The three steps to form a new phosphodiester bond during ligation are: enzyme adenylylation, adenylyl transfer to DNA, and nick sealing. Mg(2+) is a cofactor for catalysis, therefore at high concentration of Mg(2+) the ligation efficiency is high. If the concentration of Mg(2+) is limited, the nick- sealing is the rate- limiting reaction of the process, and adenylylated DNA intermediate stays in the solution. Such adenylylation of the enzyme restrains the rebinding to the adenylylated DNA intermediate comparison of an Achilles' heel of LIG1, and represents a risk if they are not fixed.
== Ecology == Many cnidarians are limited to shallow waters because they depend on endosymbiotic algae for much of their nutrients. The life cycles of most have polyp stages, which are limited to locations that offer stable substrates. Nevertheless, major cnidarian groups contain species that have escaped these limitations. Hydrozoans have a worldwide range: some, such as Hydra, live in freshwater; Obelia appears in the coastal waters of all the oceans; and Liriope can form large shoals near the surface in mid-ocean. Among anthozoans, a few scleractinian corals, sea pens and sea fans live in deep, cold waters, and some sea anemones inhabit polar seabeds while others live near hydrothermal vents over 10 km (33,000 ft) below sea-level. Reef-building corals are limited to tropical seas between 30°N and 30°S with a maximum depth of 46 m (151 ft), temperatures between 20 and 28 °C (68 and 82 °F), high salinity, and low carbon dioxide levels. Stauromedusae, although usually classified as jellyfish, are stalked, sessile animals that live in cool to Arctic waters. Cnidarians range in size from a mere handful of cells for the parasitic myxozoans through Hydra's length of 5–20 mm (1⁄4–3⁄4 in), to the lion's mane jellyfish, which may exceed 2 m (6 ft 7 in) in diameter and 75 m (246 ft) in length. Prey of cnidarians ranges from plankton to animals several times larger than themselves. Some cnidarians are parasites, mainly on jellyfish but a few are major pests of fish. Others obtain most of their nourishment from endosymbiotic algae or dissolved nutrients.
During the beta phase, the game underwent multiple updates, introducing new weapons and a completely redesigned interface based on Valve's VGUI2 technology. Additionally, the official bot, developed by Turtle Rock Studios for Counter-Strike: Condition Zero, was publicly tested within Counter-Strike 1.6 from June 5. After more than six months of public testing, the beta phase concluded on September 9, 2003. The final release of Counter-Strike 1.6 was initially scheduled for the following day, but last-minute changes to the Steam network caused a brief delay. The final version, along with the Steam client, was officially launched on September 12, 2003. Following release, advertisements were brought to Counter-Strike. They were removed after the game was converted to the SteamPipe content delivery system. Plans for Counter-Strike 1.7—which aimed to merge the player bases of Counter-Strike and Condition Zero—were never realized. In February 2013, Valve ported Counter-Strike onto OS X and Linux. It is the second Valve game to be ported to Linux, after Team Fortress 2.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.